CRISPR Therapeutics claims safety advantage in first big look at off-the-shelf CAR-T data, but durability in question
CRISPR Therapeutics CEO Samarth Kulkarni thinks his company might have built the safest CAR-T therapy yet.
The gene editing biotech announced the first major batch of data from its off-the-shelf CAR-T program, showing that 58% of the 26 large B-cell lymphoma patients who received the therapy saw their tumors shrink and that 38% had no signs of cancer whatsoever.
Those response rates, outside experts say, are broadly in the range seen in trials for autologous CAR-T therapies such as Novartis’s Kymriah and Gilead’s Yescarta, bolstering the chance that off-the-shelf could eventually make the benefits of such therapies far more widely available. Uptake of the first-generation of CAR-Ts continues to be limited by the cost, time and infrastructure required to handle each person’s cells.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.